Price increases for functional polymers for pharmaceutical applications
The Pharma Polymers business line, part of Evonik Röhm GmbH, a subsidiary of Evonik Industries AG, Essen, will implement price increases for its methyl methacrylate-based polymers for pharmaceutical applications by up to 12% for their global EUDRAGIT® business, effective January 1, 2011.
The company’s priority is to enhance the quality and availability of supply and services. In this context significant investments were made to improve reliability, and to satisfy more stringent regulatory requirements. Additionally, increased wages and raw material costs are already above pre 2009 levels.
These investments will further improve the company’s infrastructure, strengthen business continuity and create competitive advantages for its pharmaceutical customers.
About Evonik
Evonik Industries is the creative industrial group from Germany. We are a global leader in our core business of specialty chemicals. In addition, Evonik is an expert in power generation from hard coal and renewable energies, and one of the largest private residential real estate companies in Germany. Our company’s performance is shaped by creativity, specialization, continuous self-renewal, and reliability.
Evonik is active in over 100 countries around the world. In its fiscal year 2009 about 39,000 employees generated sales of about €13.1 billion and an operating profit (EBITDA) of about €2.0 billion.
Disclaimer
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.